Seung Cheol Lee1, Michal Marzec2, Xiabin Liu2, Suzanne Wehrli3, Mariusz Wasik2, Jerry David Glickson1
1Department of Radiology, University of Pennsylvania, Philadelphia, PA, United States; 2Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, United States; 3NMR Core Facility, Children's Hospital of Philadelphia, Philadelphia, PA, United States
More and more drugs for cancer are being developed in the context of signaling transduction. Some of such drugs are already in clinical trial. A noninvasive method to early detect the effect of these drugs is demanding. NMR is a promising candidate to meet this request as it can be applied in vivo to measure metabolic perturbations in tumors following various therapies. We're investigating to see effects of the inhibitor of mammalian target of rapamycin (mTOR) which is a highly conserved serine/threonine kinase that controls cell growth and metabolism in response to nutrients, growth factors, cellular energy, and stress.